Posted by Michael Wonder on 26 Aug 2022
Agenda for the September 2022 PBAC intracycle meeting
26 August 2022 - The agenda for the September 2022 PBAC intracycle meeting is now available.
The PBAC will consider (re)submissions for the following technologies:
- Azacitidine - early resolution resubmission following rejection last month
- Influenza vaccine (quadrivalent, adjuvanted) - new formulation. Initial submission was withdrawn.
- Ruxolitinib phosphate - early resolution resubmission for two patient populations following recommendation and rejection last month
- Tixagevimab and cilgavimab - new combination product
- Vosoritide - early resolution resubmission following rejection last month
All bar one medicine nominated by the PBAC las month for the Early Resolution Resubmission pathway are included in the agenda for next month's meeting.
